SOURCE: Noble Financial Capital Markets

Noble Financial Capital Markets

August 17, 2012 14:15 ET

Noble Financial Investor Conference Features Leaders in Medical Innovation

STAMFORD, CT--(Marketwire - Aug 17, 2012) - On the 24th and 25th of next month, Noble Financial Capital Markets (Noble) will host BIOX, a life sciences investor exposition to be held at the University of Connecticut in Stamford, CT. In addition to the top executives from 30 life sciences companies, leading scientists and opinion leaders in immunotherapy, targeted oncology and regenerative medicine will be participating. Among these individuals are world-renowned Dr. Phil Greenberg from the Fred Hutchinson Cancer Center and Dr. Charles Vacanti from Harvard Medical School. The first day will feature four, one-hour panel presentations, organized breakout sessions and an evening networking event. Day two is reserved for private meetings between executives and institutional investors.

"While there are conferences far bigger than BIOX, few are as focused on the rich science of medical innovation," said Rahul Jasuja, PhD, Noble's Senior Biotechnology Research Analyst. "Market capitalization and liquidity had little to do with the selection of companies to attend and to participate on the panels," he said. "Our goal is to introduce institutional investors to emerging technologies backed by scientific rigor that provides favorable risk/reward opportunities."

Alliance for Regenerative Medicine (ARM) signed on as a supporter of BIOX and has direct involvement in both the content and composition of the regenerative medicine panels being featured at the Exposition. ARM is a multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving developments in regenerative medicine. ARM and its member-companies represent the next major wave of medical innovation.

Morrie Ruffin, who co-founded ARM and is its Managing Director, feels that Noble's approach strategically aligns with the objectives of the Alliance. "Through their Exposition, Noble is focusing on promoting a better understanding of the science behind regenerative medicine companies," said Ruffin. "Many of the attending companies represent new and novel advancements in medicine and have complex and sophisticated stories," he added. "These are the stories that institutional investors need to hear as they plan their future portfolios." The Alliance membership is made up of both small and large, public and private companies including pharmaceutical giants such as Johnson and Johnson, Pfizer, Roche and Shire.

For more information about ARM:

Conference website:

Contact Information